News | Atrial Fibrillation | May 18, 2018

Botulinum Toxin Injection in CABG Patients Reduces AFib After Cardiac Surgery

Botulinum Toxin (botox) Injection in CABG Patients Reduces AFib After Cardiac Surgery. #HRS2018

Figure 1: At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group

 

May 18, 2018 — Three year results of a study found injection of botulinum toxin into epicardial fat pads in patients undergoing coronary artery bypass grafting (CABG) has resulted in substantial atrial fibrillation (AF) suppression. The results were presented at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions. 

There was sustained substantial reduction of atrial tachyarrhythmia incidence and AF burden in the early post-operative period, at one-year and three-year follow-up, data show.[1] This was accompanied by reduction in hospitalizations and major clinical adverse events. A large-scale multicenter randomized trial is needed to focus on hard clinical outcomes to more comprehensively test the value of botulinum toxin injections during cardiac surgery.

The study included 60 patients with history of paroxysmal AF and indications for CABG were randomized to either botulinum toxin (50U/1 ml at each fat pad; botox group; n=30) or placebo (0.9 percent normal saline, 1 ml at each fat pad; placebo group n=30) injections into four posterior epicardial fat pads. All patients received an ICM with regular follow-up. The primary endpoint of the extended follow up was incidence of any atrial tachyarrhythmia including AF and atrial tachycardia after 30 days of procedure until 36 months on no antiarrhythmic drugs. The secondary endpoints included clinical events and AF burden.

At the end of 36 months, the incidence of any atrial tachyarrhythmia was 23.3 percent in the botox group, as compared to 50 percent in the placebo group (hazard ratio 0.36, 95 percent confidence interval 0.14-0.88, p= 0.026) See figure 1. The three-year AF burden was significantly lower in the botox group compared to the placebo group: 1.4 vs 6.9 percent (p < 0.001). In botox group, two (7 percent) patients were hospitalized during follow-up compared to 10 (33 percent) in placebo group (p=0.02); and there were no major clinical adverse events in botox group versus four patients (13 percent) in placebo group who developed stroke or died (p=0.1).

Find links to all the Heart Rhythm 2018 Late-breaking Studies

 

Reference:

1. Evgeny Pokushalov, Boris Kozlov, Alexander Romanov, et al. Long-Term Suppression of Atrial Fibrillation by Botulinum Toxin Injection into Epicardial Fat Pads in Patients Undergoing Cardiac Surgery: One Year Follow Up of a Randomized Pilot Study. Circulation: Arrhythmia and Electrophysiology. 2015;CIRCEP.115.003199. https://doi.org/10.1161/CIRCEP.115.003199
Originally published October 20, 2015.

Related Content

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...